American Journal of Obstetrics & Gynecology
Volume 197, Issue 3, Supplement , Pages S42-S55 , September 2007

International recommendations on antiretroviral drugs for treatment of HIV-infected women and prevention of mother-to-child HIV transmission in resource-limited settings: 2006 update

  • Halima Dao, MD, MSc

      Affiliations

    • Centers for Disease Control and Prevention, National Center for HIV, Hepatitis, STD, TB Prevention, Atlanta, GA
    • Corresponding Author InformationReprints: Halima Dao, MD, MSc, Centers for Disease Control and Prevention/National Center for HIV, Hepatitis, STD, TB Prevention/Global AIDS Program/Prevention of Mother-to-Child Transmission of HIV Team, 1600 Clifton Rd, MS E-04, Atlanta, GA
    • ,
  • Lynne M. Mofenson, MD

      Affiliations

    • Pediatric, Adolescent and Maternal AIDS Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD
    • ,
  • Rene Ekpini, MD, MPH

      Affiliations

    • World Health Organization, HIV Department, Geneva, Switzerland
    • ,
  • Charles F. Gilks, DPhil, FRCP

      Affiliations

    • World Health Organization, HIV Department, Geneva, Switzerland
    • ,
  • Matthew Barnhart, MD

      Affiliations

    • United States Agency for International Development (USAID), Office of HIV/AIDS, Division of Technical Leadership and Research, Washington, DC.
    • ,
  • Omotayo Bolu, MBBS, MSc

      Affiliations

    • Centers for Disease Control and Prevention, National Center for HIV, Hepatitis, STD, TB Prevention, Atlanta, GA
    • ,
  • Nathan Shaffer, MD

      Affiliations

    • Centers for Disease Control and Prevention, National Center for HIV, Hepatitis, STD, TB Prevention, Atlanta, GA

Received 14 December 2006 ,Accepted 1 March 2007.

References 

  1. de Cock KM, Fowler MG, Mercier E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries translating research into policy and practice. JAMA. 2000;283:1175–1182
  2. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment: Pediatric AIDS Clinical Trials Group Protocol 076 study group. N Engl J Med. 1994;331:1173–1180
  3. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002;29:484–494
  4. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants in resource-limited settings: toward universal access (Recommendations for a public health approach). Geneva: World Health Organization; 2006;
  5. Gilks CF, Crowley S, Ekpini R, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet. 2006;368:505–510
  6. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access: recommendations for a public health approach. Geneva: World Health Organization; 2006;
  7. World Health Organization. Antiretroviral therapy of HIV infection in infants and children in resource-limited settings: towards universal access (Recommendations for a public health approach). Geneva: World Health Organization; 2006;
  8. Perinatal HIV Guidelines Working GroupPublic Health Service Task Force. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. 2006;October 12. Available at http://aidsinfo.nih.gov/contentfiles/PerinatalGL.pdf. Accessed April 5, 2007.
  9. Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial: Bangkok Collaborative Perinatal HIV Transmission study group. Lancet. 1999;353:773–780
  10. Lallemant M, Jourdain G, Le Coeur S, et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1: Perinatal HIV Prevention Trial (Thailand) investigators. N Engl J Med. 2000;343:982–991
  11. Wiktor SZ, Ekpini E, Karon JM, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d’Ivoire: a randomised trial. Lancet. 1999;353:781–785
  12. Dabis F, Msellati P, Meda N, et al. 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d’Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial (DITRAME study group: diminution de la transmission mere-enfant). Lancet. 1999;353:786–792
  13. Leroy V, Karon JM, Alioum A, et al. Twenty-four month efficacy of a maternal short-course zidovudine regimen to prevent mother-to-child transmission of HIV-1 in West Africa. AIDS. 2002;16:631–641
  14. Petra Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Lancet. 2002;359:1178–1186
  15. Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet. 2003;362:859–868
  16. Moodley D, Moodley J, Coovadia H, et al. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis. 2003;187:725–735
  17. Lallemant M, Jourdain G, Le Coeur S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med. 2004;351:217–228
  18. Dabis F, Bequet L, Ekouevi DK, et al. Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission. AIDS. 2005;19:309–318
  19. Taha TE, Kumwenda NI, Gibbons A, et al. Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial. Lancet. 2003;362:1171–1177
  20. Taha TE, Kumwenda NI, Hoover DR, et al. Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial. JAMA. 2004;292:202–209
  21. Cressey TR, Jourdain G, Lallemant MJ, et al. Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr. 2005;38:283–288
  22. Fowler MG, Newell ML. Breast-feeding and HIV-1 transmission in resource-limited settings. J Acquir Immune Defic Syndr. 2002;30:230–239
  23. Chung MH, Kiarie JN, Richardson BA, Lehman DA, Overbaugh J, John-Stewart GC. Breast milk HIV-1 suppression and decreased transmission: a randomized trial comparing HIVNET 012 nevirapine versus short-course zidovudine. AIDS. 2005;19:1415–1422
  24. Gray GE, Urban M, Chersich MF, et al. A randomized trial of two postexposure prophylaxis regimens to reduce mother-to-child HIV-1 transmission in infants of untreated mothers. AIDS. 2005;19:1289–1297
  25. Shapiro R, Thior I, Gilbert P, et al. Maternal single-dose nevirapine may not be needed to reduce mother-to-child HIV transmission in the setting of maternal and infant zidovudine and infant single-dose nevirapine: results of a randomized clinical trial in Botswana. [abstract] In: 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 22-25. 2005;(abstract 74LB). Available at: http://www.retroconference.org/2005/cd/Abstracts/25776.htm. Accessed April 5, 2007.
  26. Shapiro RL, Thior I, Gilbert PB, et al. Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana. AIDS. 2006;20:1281–1288
  27. Dorenbaum A, Cunningham CK, Gelber RD, et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA. 2002;288:189–198
  28. Tonwe-Gold B, Ekouevi D, Rouet F, et al. Highly active antiretroviral therapy for prevention of perinatal HIV transmission in Africa: mother to child HIV transmission plus, Abidjan, Cote d’Ivoire, 2003-2004. [abstract] In: 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 22-25. 2005;(abstract 785). Available at: http://www.retroconference.org/2005/cd/Abstracts/25191.htm. Accessed April 5, 2007.
  29. Palombi L, Germano P, Liotta G, et al. DREAM Program: 6-month follow-up of the prevention of mother to child transmission service. [abstract] In: 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, February 5-8. 2006;(abstract 723). Available at: http://www.retroactiveconference.org/2006/Abstracts/27332.htm. Accessed April 5, 2007.
  30. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS. 2001;15:1951–1957
  31. Eshleman SH, Guay LA, Mwatha A, et al. Characterization of nevirapine resistance mutations in women with subtype A vs D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012). J Acquir Immune Defic Syndr. 2004;35:126–130
  32. Lee EJ, Kantor R, Zijenah L, et al. Breast-milk shedding of drug-resistant HIV-1 subtype C in women exposed to single-dose nevirapine. J Infect Dis. 2005;192:1260–1264
  33. Loubser S, Balfe P, Sherman G, Hammer S, Kuhn L, Morris L. Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. AIDS. 2006;20:995–1002
  34. Palmer S, Boltz V, Martinson N, et al. Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc Natl Acad Sci U S A. 2006;103:7094–7099
  35. Johnson JA, Li JF, Morris L, et al. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis. 2005;192:16–23
  36. Flys T, Nissley DV, Claasen CW, et al. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis. 2005;192:24–29
  37. Lyons FE, Coughlan S, Byrne CM, Hopkins SM, Hall WW, Mulcahy FM. Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy. AIDS. 2005;19:63–67
  38. World Health Organization. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. Geneva: World Health Organization; 2006;Available at: http://www.who.int/hiv/pub/guidelines/WHO%20HIV%20Staging.pdf. Accessed April 5, 2007.
  39. Chaix M, Dabis F, Ekouevi D, et al. Addition of 3 days of ZDV+3TC postpartum to a short course of ZDV+3TC and single-dose NVP provides low rate of NVP resistance mutations and high efficacy in preventing pre-partum HIV-1 transmission: ANRS DITRAME Plus, Abidjan, Cote d’Ivoire. [abstract] In: 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 22-25. 2005;(abstract 72LB). Available at: http://www.retroconference.org/2005/cd/Abstracts/25790.htm. Accessed April 5, 2007.
  40. McIntyre J, Martinson N, Gray G, et al. Addition of short course Combivir to single dose Viramune for the prevention of mother to child transmission of HIV-1 can significantly decrease the subsequent development of maternal and paediatric NNRTI-resistant virus. [abstract] In: 3rd international AIDS Society Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, July 24-27. 2005;(abstract TuFo0204). Available at: http://www.iasociety.org/abstract/show.asp?abstract_id=2176901. Accessed April 5, 2007.
  41. Eure C, Bakaki P, McConnell M, et al. Effectiveness of repeat single-dose nevirapine in subsequent pregnancies among Ugandan women. [abstract] In: 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, February 5-8. 2006;(abstract 125). Available at: http://www.retroconference.org/2006/Abstracts/26676.htm. Accessed April 5, 2007.
  42. Martinson N, Ekouevi D, Gray G, et al. Effectiveness of single-dose nevirapine in consecutive pregnancies in Soweto and Abidjan. [abstract] In: 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, February 5-8. 2006;(abstract 722). Available at: http://www.retroconference.org/2006/Abstracts/26408.htm. Accessed April 5, 2007.
  43. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med. 2004;351:229–240
  44. Lockman S, Shapiro R, Smeaton L, et al. Response to antiretroviral therapy after single, peripartum dose of nevirapine. N Engl J Med. 2007;356:135–147
  45. Coovadia A, Marais B, Abrams E, et al. Virologic response to NNRTI treatment among women who took single-dose nevirapine 18 to 36 months earlier. [abstract] In: 13th Conference on Retroviruses and Opportunistic Infection. Denver, CO, February 5-8. 2006;(abstract 641). Available at: http://www.retroconference.org/2006/Abstracts/27071.htm. Accessed April 5, 2007.
  46. Bedikou G, Viho I, Tonwe-Gold B, et al. 6-month immunological response with HAART-containing nevirapine in HIV positive women post-exposure to single-dose of nevirapine for PMTCT (The MTCT-Plus Initiative in Abidjan, Cote d’Ivoire (2003-2005)). In: 3rd IAS Conference on HIV pathogenesis and treatment. Rio de Janeiro, Brazil, July 24, 25. 2005;/abstract MoOa0203). Available at: http://www.iasociety.org/abstract/show.asp?abstract_id=2177559. Accessed on April 5, 2007.
  47. Zijenah L, Kadzirange G, Rusakaniko S, et al. Community-based generic antiretroviral therapy following single-dose nevirapine or short-course AZT in Zimbabwe. [abstract] In: 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 22-25. 2005;(abstract 632). Available at: http://www.retroconference.org/2005/cd/Abstracts/24842.htm. Accessed April 5, 2007.
  48. Botto LD, Moore CA, Khoury MJ, Erickson JD. Neural-tube defects. N Engl J Med. 1999;341:1509–1519
  49. Saitoh A, Hull AD, Franklin P, Spector SA. Myelomeningocele in an infant with intrauterine exposure to efavirenz. J Perinatol. 2005;25:555–556
  50. Fundaro C, Genovese O, Rendeli C, Tamburrini E, Salvaggio E. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS. 2002;16:299–300
  51. de Santis M, Carducci B, de Santis L, Cavaliere AF, Straface G. Periconceptional exposure to efavirenz and neural tube defects. Arch Intern Med. 2002;162:355
  52. World Health Organization. Interim WHO clinical staging of HIV/AIDS and HIV/AIDS case definition for surveillance: African region. Geneva: World Health Organization; 2005;WHO/HIV/2005.02. Available at: https://www.who.int.hiv/pub/guidelines/clinicalstaging.pdf. Accessed April 5, 2007.
  53. Baylor M, Truffa M, Gibbs N. Hepatic toxicity of antiretrovirals in HIV-infected pregnant women: a review of the FDA’s adverse event reporting system. [abstract] In: 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 8-11. 2004;(abstract 944). Available at: http://www.retroconference.org/2004/cd/Abstract/944.htm. Accessed April 5, 2007.
  54. Baylor MS, Johann-Liang R. Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr. 2004;35:538–539
  55. Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr. 2003;34(suppl):S21–S33
  56. Stern J, Love J, Robinson P, et al. Hepatic safety of nevirapine: results of the Boehringer Ingelheim viramune hepatic safety project. [abstract] In: XIV International AIDS Conference Barcelona, Spain, July 7-12. 2002;(abstract LbOr15). Available at: http://www.medscape.com/viewarticle/44353.
  57. World Health Organization. WHO HIV and infant feeding technical consultation consensus statement. Geneva: World Health Organization; 2006;Available at: http://www.who.int/child-adolescent-health/New_Publications/NUTRITION/Consensus_Statement.pdf. Accessed April 5, 2007.
  58. World Health Organization. New data on the prevention of mother-to-child transmission of HIV and their policy implications: conclusions and recommendations (WHO Technical Consultation on Behalf of the UNFPA/UNICEF/WHO/UNAIDS Inter-Agency Task Team on Mother-to-child Transmission of HIV). Geneva: World Health Organization; 2001;
  59. Shapiro RL, Holland DT, Capparelli E, et al. Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment. J Infect Dis. 2005;192:720–727
  60. Shapiro RL, Ndung’u T, Lockman S, et al. Highly active antiretroviral therapy started during pregnancy or postpartum suppresses HIV-1 RNA, but not DNA, in breast milk. J Infect Dis. 2005;192:713–719
  61. Koulinska IN, Villamor E, Chaplin B, et al. Transmission of cell-free and cell-associated HIV-1 through breast-feeding. J Acquir Immune Defic Syndr. 2006;41:93–99
  62. Gaillard P, Fowler MG, Dabis F, et al. Use of antiretroviral drugs to prevent HIV-1 transmission through breast-feeding: from animal studies to randomized clinical trials. J Acquir Immune Defic Syndr. 2004;35:178–187
  63. Kilewo C, Karlsson K, Massawe A, et al. Prevention of mother to child transmission of HIV-1 through breastfeeding by treating infants prophylactically with lamivudine in Dar es Salaam, Tanzania. [abstract] In: 3rd IAS Conference on HIV pathogenesis and treatment, July 24-27. 2005;(abstract TuPe5.3P01). Available at: http://www.iasociety.org/abstract/show.asp?abstract_id=2176923. Accessed April 5, 2007.
  64. Vyankandondera J, Luchters S, Hassink E, et al. Reducing risk of HIV-1 transmission from mother to infant through breastfeeding using antiretroviral prophylaxis in infants (SIMBA-study). [abstract] In: 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, France, July 13-16. 2003;(abstract LB07). Available at: http://www.iasociety.org/abstract/show.asp?abstract_id=11061. Accessed April 5, 2007.
  65. Thior I, Lockman S, Smeaton LM, et al. Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi study. JAMA. 2006;296:794–805

PII: S0002-9378(07)00291-8

doi: 10.1016/j.ajog.2007.03.001

American Journal of Obstetrics & Gynecology
Volume 197, Issue 3, Supplement , Pages S42-S55 , September 2007

Article Tools